

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



# ClouDr Group Limited

## 智雲健康科技集團\*

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 9955)**

### **VOLUNTARY ANNOUNCEMENT STRATEGIC COOPERATION AGREEMENT WITH A SUBSIDIARY OF CR SANJIU**

This announcement is made by ClouDr Group Limited (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) on a voluntary basis. The board of directors (the “**Directors**”) of the Company (the “**Board**”) is pleased to announce that the Company entered into a non-legally binding strategic cooperation agreement (the “**Strategic Cooperation Agreement**”) with 昆明華潤聖火藥業有限公司 (China Resources Kunming Shenghuo Pharmaceutical Co., Ltd.\*) (“**CR Shenghuo**”), a wholly-owned subsidiary of 華潤三九醫藥股份有限公司 (China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.\*) (“**CR Sanjiu**”), on March 5, 2024.

CR Sanjiu (SZSE: 000999) is a large listed state-controlled pharmaceutical company and principally engaged in the research and development, production and sales of pharmaceutical products and related health services. It has 28 types of pharmaceutical products with annual sales of more than RMB100 million. CR Shenghuo, which became a wholly-owned subsidiary of CR Sanjiu in September 2016, has been stepping up its presence in the chronic disease field for many years. Its main product is Lixuwang<sup>®</sup> Xuesaitong Soft Capsule, with focus on cardiovascular and cerebrovascular diseases and endocrine diseases (mainly diabetes).

Pursuant to the Strategic Cooperation Agreement, the Group will become the sole agent of CR Shenghuo’s Lixuwang<sup>®</sup> Xuesaitong Soft Capsule in hospitals in the core provinces of sales and distribution of the product for a term of three years. During the period of the cooperation, the Company will fully rely on its strengths in digitization and well-established hospital channel resources to further enhance patient access and promotional efficiency of Lixuwang<sup>®</sup> Xuesaitong Soft Capsule and to improve the brand power of such product.

The Board is of the view that the Strategic Cooperation Agreement provides valuable opportunities for the parties to utilize their respective resources and expertise to create mutual benefits and synergies for each other. Accordingly, the Board is of the view that the entering into of the Strategic Cooperation Agreement is in the interests of the Company and its shareholders as a whole.

### **Information on Lixuwang<sup>®</sup> Xuesaitong Soft Capsule (Guo Yao Zhun Zi Z19990022)**

Lixuwang<sup>®</sup> Xuesaitong Soft Capsule is commonly used for the prevention and treatment of cardiovascular and cerebrovascular diseases in clinical settings. Clinical observations over the years have shown that Lixuwang<sup>®</sup> Xuesaitong Soft Capsule has significant efficacy in the treatment of cerebral ischemic stroke, coronary heart disease and other diseases. The product is recommended by a number of clinical guidelines, including the Guidelines on Stable Angina Caused by Coronary Heart Disease for Traditional Chinese Medicine Practitioners (2019), the Guidelines on Rational Drug Use for Stroke in China (2021), the Guidelines on the Prevention and Treatment of Stroke in China (2nd Edition), and the Guidelines on Clinical Diagnosis and Treatment of Diabetic Peripheral Neuropathy for Traditional Chinese Medicine Practitioners (2016).

To the best of the Board's knowledge, information and belief after having made all reasonable enquiries, both CR Sanjiu and CR Shenghuo are third parties independent of the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")). The Company will make further announcement(s) on the potential cooperation as and when appropriate in compliance with the Listing Rules. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board  
**ClouDr Group Limited**  
**Kuang Ming**

*Chairman, Executive Director and Chief Executive Officer*

Hong Kong, March 6, 2024

*As at the date of this announcement, the Board comprises Mr. Kuang Ming as the executive Director, Mr. Lee Kar Chung Felix as the non-executive Director, and Dr. Hong Weili, Mr. Zhang Saiyin and Mr. Ang Khai Meng as the independent non-executive Directors.*

\* *For identification purpose only*